About this episode

Heart failure pharmacists debate the role of MRAs in HFpEF and HFmrEF, discussing trial data and treatment options.

In this lively debate, heart failure pharmacists Stormi Gale, PharmD and Robert L Page II, PharmD examine the role of MRAs in HFpEF and HFmrEF. From trial data and cost considerations to CKM overlap and hyperkalemia risk, they explore whether finerenone represents a new pillar - or whether spironolactone remains the practical choice.

Explore listener stats, chart rankings, contacts and more on the Heart Failure Beat podcast page.